Progressive supranuclear palsy

Handbook of Clinical Neurology

Volumn 84, Issue , 2007, Pages 327-349

  Burn, David J ^a   Lees, Andrew J ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649349608     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(07)84047-4     Document Type: Chapter

References (199)

1. Aarsland D., Litvan I., Salmon D., et al. Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry 74 (2003) 1215-1220
2. Albers D.S., and Augood S.J. New insights into progressive supranuclear palsy. Trends Neurosci 24 (2001) 347-353
3. Arai T., Ikeda K., Akiyama H., et al. Identification of amino-terminally cleaved tau fragments that distinguish progressive supranuclear palsy from corticobasal degeneration. Ann Neurol 55 (2004) 72-79
4. Averbuch-Heller L., Paulson G.W., Daroff R.B., et al. Whipple's disease mimicking progressive supranuclear palsy: the diagnostic value of eye movement recording. J Neurol Neurosurg Psychiatry 66 (1999) 532-535
5. Baker K.B., and Montgomery E.B. Performance on the PD test battery by relatives of patients with progressive supranuclear palsy. Neurology 56 (2001) 25-30
6. Baker M., Litvan I., Houlden H., et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 8 (1999) 711-715
7. Barclay C.L., and Lang A.E. Dystonia in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 62 (1997) 352-356
8. Barclay C.L., Duff J., Sandor P., et al. Limited usefulness of electroconvulsive therapy in progressive supranuclear palsy. Neurology 46 (1996) 1284-1286
9. Birdi S., Rajput A.H., Fenton M., et al. Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord 17 (2002) 1255-1264
10. Blin J., Baron J.C., Dubois B., et al. Positron emission tomography study in progressive supranuclear palsy: brain hypometabolic pattern and clinicometabolic correlations. Arch Neurol 47 (1990) 747-752
11. Boeve B.F., Silber M.H., Parisi J.E., et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology 61 (2003) 40-45
12. Bonuccelli U., Piccini P., Del Dotto P., et al. Apomorphine test in de novo Parkinson's disease. Funct Neurol 7 (1992) 295-298
13. Borghi R., Piccini A., Delacourte A., et al. Protein levels of glycogen synthase 3 kinase are normal in progressive supranuclear palsy. Neurosci Lett 366 (2004) 67-70
14. Bower J.H., Maraganore D.M., McDonnell S.K., et al. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 49 (1997) 1284-1288
15. Brenneis C., Seppi K., Schocke M., et al. Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 75 (2004) 246-249
16. Brodsky H., Dat Vuong K., Thomas M., et al. Glabellar and palmomental reflexes in Parkinsonian disorders. Neurology 63 (2004) 1096-1098
17. Brotini S., and Gigli G.L. Epidemiology and clinical features of sleep disorders in extrapyramidal disease. Sleep Med 5 (2004) 169-179
18. Brusa A., Stoehr R., and Pramstaller P.P. Progressive supranuclear palsy: new disease or variant of postencephalitic parkinsonism?. Mov Disord 19 (2004) 247-252
19. Burn D.J., Rinne J.O., Quinn N.P., et al. Striatal opioid receptor binding in Parkinson's disease, striatonigral degeneration and Steele-Richardson-Olszewski syndrome. A [11C]diprenorphine PET study. Brain 118 (1995) 951-958
20. Campdelacreu J., Kumru H., Tolosa E., et al. Progressive supranuclear palsy syndrome induced by clebopride. Mov Disord 19 (2004) 482-484
21. Caparros-Lefebvre D., and Elbaz A. Caribbean Parkinsonism Study Group. Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Lancet 354 (1999) 281-286
22. Caparros-Lefebvre D., Sargent N., Lees A.J., et al. Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy. Brain 125 (2002) 801-811
23. Chiò A., Magnani C., and Schiffer D. Prevalence of Parkinson's disease in Northwestern Italy: comparison of tracer methodology and clinical ascertainment of cases. Mov Disord 13 (1998) 400-405
24. Clarke C.E., and Lowry M. Systematic review of proton magnetic resonance spectroscopy of the striatum in parkinsonian syndromes. Eur J Neurol 8 (2001) 573-577
25. Collins S.J., Ahlskog J.E., Parisi J.E., et al. Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria. J Neurol Neurosurg Psychiatry 58 (1995) 167-173
26. Conrad C., Andreadis A., Trojanowski J.Q., et al. Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol 41 (1997) 277-281
27. Daniele A., Moro E., and Bentivoglio A.R. Zolpidem in progressive supranuclear palsy. N Engl J Med 341 (1999) 543-544
28. Davidson B.L., and Paulson H.L. Molecular medicine for the brain: silencing of disease genes with RNA interference. Lancet Neurol 3 (2004) 145-149
29. Davis P.H., Bergeron C., and McLachlan D.R. Atypical presentation of progressive supranuclear palsy. Ann Neurol 17 (1985) 337-343
30. D'Costa D.F., Abbott R.J., Pye I.F., et al. The apomorphine test in Parkinsonian syndromes. J Neurol Neurosurg Psychiatry 54 (1991) 870-872
31. De Bruin V.M., and Lees A.J. Subcortical neurofibrillary degeneration presenting as Steele-Richardson-Olszewski and other related syndromes: a review of 90 pathologically verified cases. Mov Disord 9 (1994) 381-389
32. de Rijk M.C., Breteler M.M.B., Graveland G.A., et al. Prevalence of Parkinson's disease in the elderly: the Rotterdam study. Neurology 45 (1995) 2143-2146
33. de Silva R., Hardy J., Crook J., et al. The tau locus is not significantly associated with pathologically confirmed sporadic Parkinson's disease. Neurosci Lett 330 (2002) 201-203
34. de Silva R., Hope A., Pittman A., et al. Strong association of the Saitohin gene Q7 variant with progressive supranuclear palsy. Neurology 61 (2003) 407-409
35. Delisle M.B., Murrell J.R., Richardson R., et al. A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsy. Acta Neuropathol (Berl) 98 (1999) 62-77
36. Dubois B., Slachevsky A., Litvan I., et al. The FAB: a frontal assessment battery. Neurology 55 (2000) 1621-1626
37. Duvoisin R.C. Clinical diagnosis. In: Litvan I., and Agid Y. (Eds). Progressive Supranuclear Palsy: Clinical and Research Approaches (1992), Oxford University Press, New York 15-33
38. Eckert T., Sailer M., Kaufmann J., et al. Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging. Neuroimage 21 (2004) 229-235
39. Eidelberg D., and Dhawan V. Can imaging distinguish PSP from other neurodegenerative disorders?. Neurology 58 (2002) 997-998
40. Engel P.A. Treatment of progressive supranuclear palsy with amitriptyline: therapeutic and toxic effects. J Am Geriatr Soc 44 (1996) 1072-1074
41. Ezquerra M., Campdelacreu J., Munoz E., Oliva R., et al. Sequence analysis of tau 3′untranslated region and saitohin gene in sporadic progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 75 (2004) 155-157
42. Fabbrini G., Barbanti P., Bonifati V., et al. Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol Scand 103 (2001) 123-125
43. Farrer M., Skipper L., Berg M., et al. The tau H1 haplotype is associated with Parkinson's disease in the Norwegian population. Neurosci Lett 322 (2002) 83-86
44. Foster N.L., Aldrich M.S., Bluemlein L., et al. Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep. Neurology 39 (1989) 257-261
45. Foster N.L., Minoshima S., Johanns J., et al. PET measures of benzodiazepine receptors in progressive supranuclear palsy. Neurology 54 (2000) 1768-1773
46. Frasca J., Blumbergs P.C., Henschke P., et al. A clinical and pathological study of progressive supranuclear palsy. Clin Exp Neurol 28 (1991) 79-89
47. Frattali C.M., Sonies B.C., Chi-Fishman G., et al. Effects of physostigmine on swallowing and oral motor functions in patients with progressive supranuclear palsy: a pilot study. Dysphagia 14 (1999) 165-168
48. Garbutt S., Riley D.E., Kumar A.N., et al. Abnormalities of optokinetic nystagmus in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 75 (2004) 1386-1394
49. Geddes J.F., Hughes A.J., Lees A.J., et al. Pathological overlap in cases of parkinsonism associated with neurofibrillary tangles. A study of recent cases of postencephalitic parkinsonism and comparison with progressive supranuclear palsy and Guamanian parkinsonism-dementia complex. Brain 116 (1993) 281-302
50. Gerhard A., Banati R.B., Cagnin A., et al. In vivo imaging of activated microglia with [11C] PK11195 positron emission tomography (PET) in idiopathic and atypical Parkinson's disease. Neurology 56 (2001) A270
51. Ghika J., Tennis M., Hoffman E., et al. Idazoxan treatment in progressive supranuclear palsy. Neurology 41 (1991) 986-991
52. Gibb G.M., de Silva R., Revesz T., et al. Differential involvement and heterogeneous phosphorylation of tau isoforms in progressive supranuclear palsy. Brain Res Mol Brain Res 121 (2004) 95-101
53. Gironell A., Kulisevsky J., Roig C., et al. Diagnostic potential of acoustic startle reflex, acoustic blink reflex, and electro-oculography in progressive supranuclear palsy: a prospective study. Mov Disord 18 (2003) 1273-1279
54. Goetz C.G. An early photographic case of probable progressive supranuclear palsy. Mov Disord 11 (1996) 617-618
55. Goetz C.G., Leurgans S., Lang A.E., et al. Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. Neurology 60 (2003) 917-922
56. Golbe L.I. Epidemiology. In: Litvan I., and Agid Y. (Eds). Progressive Supranuclear Palsy: Clinical and Research Approaches (1992), Oxford University Press, Oxford 34-43
57. Golbe L.I. Progressive supranuclear palsy. In: Jankovic J., and Tolosa E. (Eds). Parkinson's Disease and Movement Disorders (1993), Williams & Wilkins, Baltimore 145-161
58. Golbe L.I. Progressive supranuclear palsy in the molecular age. Lancet 356 (2000) 870-871
59. Golbe L.I., Davis P.H., Schoenberg B.S., et al. Prevalence and natural history of progressive supranuclear palsy. Neurology 38 (1988) 1031-1034
60. Golbe L.I., Sage J.I., and Duvoisin R.C. Drug treatment of 83 patients with progressive supranuclear palsy. Neurology 40 (1990) 438
61. Goldbaum O., Oppermann M., Handschuh M., et al. Proteasome inhibition stabilizes tau inclusions in oligodendroglial cells that occur after treatment with okadaic acid. J Neurosci 23 (2003) 8872-8880
62. Grafman J., Litvan I., and Stark M. Neuropsychological features of progressive supranuclear palsy. Brain Cogn 28 (1995) 311-320
63. Groschel K., Hauser T.K., Luft A., et al. Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration. Neuroimage 21 (2004) 714-724
64. Hartzler A.W., Zhu X., Siedlak S.L., et al. The p38 pathway is activated in Pick disease and progressive supranuclear palsy: a mechanistic link between mitogenic pathways, oxidative stress, and tau. Neurobiol Aging 23 (2002) 855-859
65. Hauser R.A., and Trehan R. Initial experience with electroconvulsive therapy for progressive supranuclear palsy. Mov Disord 9 (1994) 467-469
66. Hauw J.J., Daniel S.E., Dickson D., et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 44 (1994) 2015-2019
67. Holmberg B., Rosengren L., Karlsson J.E., et al. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease. Mov Disord 13 (1998) 70-77
68. Holmberg B., Johnels B., Ingvarsson P., et al. CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of Parkinsonian syndromes. Parkinsonism Relat Disord 8 (2001) 23-31
69. Holmberg B., Johnels B., Blennow K., et al. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord 18 (2003) 186-190
70. +1 protein in progressive supranuclear palsy in humans. Neurosci Lett 359 (2004) 94-98
71. Horiguchi T., Uryu K., Giasson B.I., et al. Nitration of tau protein is linked to degeneration in tauopathies. Am J Pathol 163 (2003) 1021-1031
72. Houlden H., Baker M., Morris H.R., et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 56 (2001) 1702-1706
73. Hughes A.J., Daniel S.E., Ben-Shlomo Y., et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125 (2002) 861-870
74. Hutton M. "Missing" tau mutation identified. Ann Neurol 47 (2000) 417-418
75. Jackson J.A., Jankovic J., and Ford J. Progressive supranuclear palsy: clinical features and response to treatment in sixteen patients. Ann Neurol 13 (1983) 273-278
76. Jankovic J. Progressive supranuclear palsy: clinical and pharmacological update. Neurol Clin 2 (1984) 473-486
77. Jellinger K.A., and Blancher C. Neuropathology. In: Litvan I., and Agid Y. (Eds). Progressive Supranuclear Palsy: Clinical and Research Approaches (1992), Oxford University Press, Oxford 44-88
78. Josephs K.A., and Dickson D.W. Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank. Mov Disord 18 (2003) 1018-1026
79. Josephs K.A., Tsuboi Y., and Dickson D.W. Creutzfeldt-Jakob disease presenting as progressive supranuclear palsy. Eur J Neurol 11 (2004) 343-346
80. Juh R., Kim J., Moon D., et al. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET. Eur J Radiol 51 (2004) 223-233
81. Katzenschlager R., Cardozo A., Cobo M., et al. Unclassifiable parkinsonism in two European tertiary referral centres for movement disorders. Mov Disord 18 (2003) 1123-1131
82. Kawashima M., Miyake M., Kusumi M., et al. Prevalence of progressive supranuclear palsy in Yonago, Japan. Mov Disord 19 (2004) 1239-1240
83. Kertzman C., Robinson D.L., and Litvan I. Effects of physostigmine on spatial attention in patients with progressive supranuclear palsy. Arch Neurol 47 (1990) 1346-1350
84. Kim Y.J., Ichise M., Ballinger J.R., et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord 17 (2002) 303-312
85. Kimber J., Mathias C.J., Lees A.J., et al. Physiological, pharmacological and neurohormonal assessment of autonomic function in progressive supranuclear palsy. Brain 123 (2000) 1422-1430
86. Kobari M., Fukuuchi Y., Shinohara T., et al. Local cerebral blood flow and its response to intravenous levodopa in progressive supranuclear palsy. Comparison with Parkinson's disease. Arch Neurol 49 (1992) 725-730
87. Koller W.C., Morantz R., Vetere-Overfield B., et al. Autologous adrenal medullary transplant in progressive supranuclear palsy. Neurology 39 (1989) 1066-1068
88. Kompoliti K., Goetz C.G., Litvan I., et al. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol 55 (1998) 1099-1102
89. Kotake Y., Okuda K., Kamizono M., et al. Detection and determination of reticuline and N-methylcoculaurine in the Annonaceae family using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 806 (2004) 75-78
90. Krack P., and Marion M.H. "Apraxia of lid opening," a focal eyelid dystonia: clinical study of 32 patients. Mov Disord 9 (1994) 610-615
91. Kristensen M.O. Progressive supranuclear palsy-20 years later. Acta Neurol Scand 71 (1985) 177-189
92. Kuhn A.A., Grosse P., Holtz K., et al. Patterns of abnormal motor cortex excitability in atypical parkinsonian syndromes. Clin Neurophysiol 115 (2004) 1786-1795
93. Lange K.W., Tucha O., Alders G.L., et al. Differentiation of parkinsonian syndromes according to differences in executive functions. J Neural Transm 110 (2003) 983-995
94. Lannuzel A., Michel P.P., Caparros-Lefebvre D., et al. Toxicity of Annonaceae for dopaminergic neurons: potential role in atypical parkinsonism in Guadeloupe. Mov Disord 17 (2002) 84-90
95. Larner A.J. Did Charles Dickens describe progressive supranuclear palsy in 1857?. Mov Disord 17 (2002) 832-833
96. Lees A.J. The Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). In: Marsden C.D., and Fahn S. (Eds). Movement Disorders 2 vol. 7 (1987), Butterworths, London 272-287
97. Lepore F.E., and Moudgil S.S. Procerus sign in progressive supranuclear palsy. Neurology 58 (2002) 1866-1867
98. Lewis J., McGowan E., Rockwood J., et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 25 (2000) 402-405
99. Litvan I. Diagnosis and management of progressive supranuclear palsy. Semin Neurol 21 (2001) 41-48
100. Litvan I., and Chase T.N. Traditional and experimental therapeutic approaches. In: Litvan I. (Ed). Progressive Supranuclear Palsy: Clinical and Research Approaches (1992), Oxford University Press, New York 254-269
101. Litvan I., Gomez C., Atack J.R., et al. Physostigmine treatment of progressive supranuclear palsy. Ann Neurol 26 (1989) 404-407
102. Litvan I., Blesa R., Clark K., et al. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy. Ann Neurol 36 (1994) 55-61
103. Litvan I., Agid Y., Calne D., et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47 (1996) 1-9
104. Litvan I., Hauw J.J., Bartko J.J., et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 55 (1996) 97-105
105. Litvan I., Mangone C.A., McKee A., et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry 60 (1996) 615-620
106. Litvan I., Campbell G., Mangone C.A., et al. Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study. Brain 120 (1997) 65-74
107. Litvan I., Phipps M., Pharr V.L., et al. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 57 (2001) 467-473
108. Litvan I., Bhatia K.P., Burn D.J., et al. SIC task force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord 18 (2003) 467-486
109. Lopez O.L., Litvan I., Catt K.E., et al. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. Neurology 53 (1999) 1292-1299
110. Maher E.R., and Lees A.J. The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 36 (1986) 1005-1008
111. Maraganore D.M., Anderson D.W., Bower J.H., et al. Potential selection bias in autopsy series of Parkinson's disease and related disorders. Neurology 50 (1998) A98-A99
112. Maraganore D.M., Hernandez D.G., Singleton A.B., et al. Case-control study of the extended tau gene haplotype in Parkinson's disease. Ann Neurol 50 (2001) 658-661
113. Mastaglia F.L., Grainger K., Kee F., et al. Progressive supranuclear palsy (the Steele-Richardson-Olszewski syndrome): clinical and electrophysiological observations in eleven cases. Proc Aust Assoc Neurol 10 (1973) 35-44
114. Masucci E.F., and Kurtzke J.F. Tremor in progressive supranuclear palsy. Acta Neurol Scand 80 (1989) 296-300
115. Matsuo H., Takashima H., Kishikawa M., et al. Pure akinesia: an atypical manifestation of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 54 (1991) 397-400
116. Mayr B.J., Bonelli R.M., Niederwieser G., et al. Zolpidem in progressive supranuclear palsy. Eur J Neurol 9 (2002) 184-185
117. Millar D., Griffiths P., Zermansky A.J., et al. Characterizing behavioral and cognitive dysexecutive changes in progressive supranuclear palsy. Mov Disord 21 (2006) 199-207
118. Mishina M., Ishii K., Mitani K., et al. Midbrain hypometabolism as early diagnostic sign for progressive supranuclear palsy. Acta Neurol Scand 110 (2004) 128-135
119. Mokri B., Ahlskog J.E., Fulgham J.R., et al. Syndrome resembling PSP after surgical repair of ascending aorta dissection or aneurysm. Neurology 62 (2004) 971-973
120. Montplaisir J., Petit D., Decary A., et al. Sleep and quantitative EEG in patients with progressive supranuclear palsy. Neurology 49 (1997) 999-1003
121. Morris H.R., Gibb G., Katzenschlager R., et al. Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy. Brain 125 (2002) 969-975
122. Morris H.R., Katzenschlager R., Janssen J.C., et al. Sequence analysis of tau in familial and sporadic progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 72 (2002) 388-390
123. Morris H.R., Osaki Y., Holton J., et al. Tau exon 10+16 mutation FTDP-17 presenting clinically as sporadic young onset PSP. Neurology 61 (2003) 102-104
124. Mudher A., Shepherd D., Newman T.A., et al. GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry 9 (2004) 522-530
125. Muller J., Wenning G.K., Wissel J., et al. Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. J Neurol 249 (2002) 300-304
126. Murialdo A., Marchese R., Abbruzzese G., et al. Neurosyphilis presenting as progressive supranuclear palsy. Mov Disord 15 (2000) 730-731
127. Nath U., and Burn D.J. The epidemiology of progressive supranuclear palsy. Parkinsonism Relat Disord 6 (2000) 145-153
128. Nath U., Ben-Shlomo Y., Thomson R., et al. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain 124 (2001) 1438-1449
129. Nath U., Ben-Shlomo Y., Thomson R.G., et al. Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology 60 (2003) 910-916
130. Nath U., Thomson R.G., Wood R., et al. Population-based mortality rates and quality of death certification in progressive supranuclear palsy (Steele-Richardson-Olszewski Syndrome). J Neurol Neurosurg Psychiatry 78 (2005) 498-502
131. Neophytides A., Lieberman A.N., Goldstein M., et al. The use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 45 (1982) 261-263
132. Netzel P.J., and Sutor B. Electroconvulsive therapy-responsive depression in a patient with progressive supranuclear palsy. J ECT 17 (2001) 68-70
133. Neumann M., Muller V., Gorner K., et al. Pathological properties of the Parkinson's disease-associated DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease. Acta Neuropathol (Berl) 107 (2004) 489-496
134. Newman G.C. Treatment of progressive supranuclear palsy with tricyclic antidepressants. Neurology 35 (1985) 1189-1193
135. Nieforth K.A., and Golbe L.I. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol 16 (1993) 338-346
136. Oka M., Katayama S., Imon Y., et al. Abnormal signals on proton density-weighted MRI of the superior cerebellar peduncle in progressive supranuclear palsy. Acta Neurol Scand 104 (2001) 1-5
137. Ondo W., Warrior D., Overby A., et al. Computerized posturography analysis of progressive supranuclear palsy: a case-control comparison with Parkinson's disease and healthy controls. Arch Neurol 57 (2000) 1464-1469
138. Osaki Y., Ben-Shlomo Y., Lees A.J., et al. Accuracy of clinical diagnosis of progressive supranuclear palsy. Mov Disord 19 (2003) 181-189
139. Pastor P., Pastor E., Carnero C., et al. Familial atypical progressive supranuclear palsy associated with homozigosity for the delN296 mutation in the tau gene. Ann Neurol 49 (2001) 263-267
140. Pastor P., Ezquerra M., Perez J.C., et al. Novel haplotypes in 17q21 are associated with progressive supranuclear palsy. Ann Neurol 56 (2004) 249-258
141. Paviour D.C., Lees A.J., Josephs K.A., et al. Frontotemporal lobar degeneration with ubiquitin-only-immunoreactive neuronal changes: broadening the clinical picture to include progressive supranuclear palsy. Brain 127 (2004) 2441-2451
142. Pezzella F.R., Paglia M.G., and Colosimo C. Cerebrospinal fluid analysis for Whipple's disease in patients with progressive supranuclear palsy. Mov Disord 19 (2004) 220-222
143. Pharr V., Litvan I., Brat D.J., et al. Ideomotor apraxia in progressive supranuclear palsy: a case study. Mov Disord 14 (1999) 162-166
144. 18Fluorodeoxyglucose positron emission tomography. Arch Neurol 58 (2001) 1846-1851
145. Piccione F., Mancini E., Tonin P., et al. Botulinum toxin treatment of apraxia of eyelid opening in progressive supranuclear palsy: report of two cases. Arch Phys Med Rehabil 78 (1997) 525-529
146. Pillon B., Dubois B., Ploska A., et al. Severity and specificity of cognitive impairment in Alzheimer's, Huntington's, and Parkinson's diseases and progressive supranuclear palsy. Neurology 41 (1991) 634-643
147. Pirker W., Djamshidian S., Asenbaum S., et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord 17 (2002) 45-53
148. Pittman A.M., Myers A.J., Duckworth J., et al. The structure of the tau haplotype in controls and in progressive supranuclear palsy. Hum Mol Genet 13 (2004) 1267-1274
149. Plotkin M., Amthauer H., Klaffke S., et al. Combined (123)I-FP-CIT and (123)I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm 112 (2005) 677-692
150. Polo K.B., and Jabbari B. Botulinum toxin-A improves the rigidity of progressive supranuclear palsy. Ann Neurol 35 (1994) 237-239
151. Quinn N.P. Parkinson's disease: clinical features. In: Quinn N.P. (Ed). Parkinsonism vol. 6 (1997), Balliere Tindall, London 1-13
152. Radhakrishnan K., Thacker A.K., Maloo J.C., et al. Descriptive epidemiology of some rare neurological diseases in Benghazi, Libya. Neuroepidemiology 7 (1988) 159-164
153. Rajput A.H., Offord K.P., Beard C.M., et al. Epidemiology of parkinsonism: incidence, classification and mortality. Ann Neurol 16 (1984) 278-282
154. Rascol O., Sieradzan K., Peyro-Saint-Paul H., et al. Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy. Mov Disord 13 (1998) 673-676
155. Reitblat T., Polishchuk I., Dorodnikov E., et al. Primary antiphospholipid antibody syndrome masquerading as progressive supranuclear palsy. Lupus 12 (2003) 67-69
156. Richter-Landsberg C., and Bauer N.G. Tau-inclusion body formation in oligodendroglia: the role of stress proteins and proteasome inhibition. Int J Dev Neurosci 22 (2004) 443-451
157. Righini A., Antonini A., De Notaris R., et al. MR imaging of the superior profile of the midbrain: differential diagnosis between progressive supranuclear palsy and Parkinson's disease. Am J Neuroradiol 25 (2004) 927-932
158. Rivaud-Pechoux S., Vidailhet M., Gallouedec G., et al. Longitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy. Neurology 54 (2000) 1029-1032
159. Rohs G. Progressive supranuclear palsy: managing the disabilities and providing nursing support. Axone 17 (1996) 60-65
160. Rojo A., Pernaute R.S., Fontan A., et al. Clinical genetics of familial progressive supranuclear palsy. Brain 122 (1999) 1233-1245
161. Romano S., and Colosimo C. Procerus sign in progressive supranuclear palsy. Neurology 57 (2001) 1928-1929
162. Rottach K.G., Riley D.E., DiScenna A.O., et al. Dynamic properties of horizontal and vertical eye movements in parkinsonian syndromes. Ann Neurol 39 (1996) 368-377
163. Sandyk R. Transcranial AC pulsed applications of weak electromagnetic fields reduces freezing and falling in progressive supranuclear palsy: a case report. Int J Neurosci 94 (1998) 41-54
164. Santacruz P., Uttl B., Litvan I., et al. Progressive supranuclear palsy: a survey of the disease course. Neurology 50 (1998) 1637-1647
165. Sasaki N., Fukatsu R., Tsuzuki K., et al. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am J Pathol 153 (1998) 1149-1155
166. Scaravilli T., Pramstaller P.P., Salerno A., et al. Neuronal loss in Onuf's nucleus in three patients with progressive supranuclear palsy. Ann Neurol 48 (2000) 97-101
167. Schleider M.A., and Nagurney J.T. Progressive supranuclear ophthalmoplegia. Association with cricopharyngeal dysfunction and recurrent pneumonia. JAMA 237 (1977) 994-995
168. Schrag A., Ben-Shlomo Y., and Quinn N.P. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 354 (1999) 1771-1775
169. Schrag A., Good C.D., Miszkiel K., et al. Differentiation of atypical Parkinsonian syndromes with routine MRI. Neurology 54 (2000) 697-702
170. 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism. Eur J Nucl Med Mol Imaging 31 (2004) 1128-1135
171. Schulz J.B., Skalej M., Wedekind D., et al. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol 45 (1999) 65-74
172. Seppi K., Schocke M.F.H., Esterhammer R., et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 60 (2003) 922-927
173. Shinotoh H., Namba H., Yamaguchi M., et al. Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy. Ann Neurol 46 (1999) 62-69
174. Soliveri P., Monza D., Paridi D., et al. Neuropsychological follow up in patients with Parkinson's disease, striatonigral degeneration-type multiple system atrophy, and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 69 (2000) 313-318
175. Sosner J., Wall G.C., and Sznajder J. Progressive supranuclear palsy: clinical presentation and rehabilitation of two patients. Arch Phys Med Rehabil 74 (1993) 537-539
176. Stanford P.M., Halliday G.M., Brooks W.S., et al. Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau gene mutations. Brain 123 (2000) 880-893
177. Stanford P.M., Brooks W.S., Teber E.T., et al. Frequency of tau mutations in familial and sporadic frontotemporal dementia and other tauopathies. J Neurol 251 (2004) 1098-1104
178. Tamai S., and Almeida O.P. Nortriptyline for the treatment of depression in progressive supranuclear palsy. J Am Geriatr Soc 45 (1997) 1033-1034
179. Tolosa E., Valldeoriola F., and Marti M.J. Clinical diagnosis and diagnostic criteria of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). J Neural Transm Suppl 42 (1994) 15-31
180. Tomasiewicz H.G., Flaherty D.B., Soria J.P., et al. Transgenic zebrafish model of neurodegeneration. J Neurosci Res 70 (2002) 734-745
181. Tsuboi Y., Slowinski J., Josephs K.A., et al. Atrophy of the superior cerebellar peduncle in progressive supranuclear palsy. Neurology 60 (2003) 1766-1769
182. Urakami K., Wada K., Arai H., et al. Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy. J Neurol Sci 183 (2001) 95-98
183. Van Gerpen J.A., Ahlskog J.E., and Petty G.W. Progressive supranuclear palsy phenotype secondary to CADASIL. Parkinsonism Relat Disord 9 (2003) 367-369
184. van Slegtenhorst M., Lewis J., and Hutton M. The molecular genetics of the tauopathies. Exp Gerontol 35 (2000) 461-471
185. Verny M., Jellinger K.A., Hauw J.J., et al. Progressive supranuclear palsy: a clinicopathological study of 21 cases. Acta Neuropathol (Berl) 91 (1996) 427-431
186. Vidailhet M., Rivaud S., Gouidier-Khouja N., et al. Eye movements in parkinsonian syndromes. Ann Neurol 35 (1994) 420-426
187. Vodusek D.B. Sphincter EMG and differential diagnosis of multiple system atrophy. Mov Disord 16 (2001) 600-607
188. Wakabayashi K., and Takahashi H. Pathological heterogeneity in progressive supranuclear palsy and corticobasal degeneration. Neuropathology 24 (2004) 79-86
189. Walter U., Niehaus L., Probst T., et al. Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes. Neurology 60 (2003) 74-77
190. Walter U., Dressler D., Wolters A., et al. Sonographic discrimination of corticobasal degeneration vs progressive supranuclear palsy. Neurology 63 (2004) 504-509
191. Ward-Smith P.A., and Berry P. Autologous transplantation as a treatment for progressive supranuclear palsy. J Neurosci Nurs 22 (1990) 100-103
192. Warmuth-Metz M., Naumann M., Csoti I., et al. Measurement of the midbrain diameter on routine magnetic resonance imaging: a simple and accurate method of differentiating between Parkinson disease and progressive supranuclear palsy. Arch Neurol 58 (2001) 1076-1079
193. Weiner W.J., Minagar A., and Shulman L.M. Pramipexole in progressive supranuclear palsy. Neurology 52 (1999) 873-874
194. Wermuth L., Joensen P., Bunger N., et al. High prevalence of Parkinson's disease in the Faroe Islands. Neurology 49 (1997) 426-432
195. Williams A.C., Nutt J., Lake C.R., et al. Actions of bromocriptine in the Shy-Drager and Steele-Richardson-Olszewksi syndromes. In: Fuxe K., and Calne D.B. (Eds). Dopaminergic Ergot Derivatives and Motor Function (1979), Pergamon Press, Oxford 271-283
196. Williams D.R., Paviour D.C., Watt H.C., et al. Characteristics of two distinct clinical phenotypes observed in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Mov Disord 19 (2004) S328-S329
197. Wittman C.W., Wszolek M.F., Shulman J.M., et al. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293 (2001) 711-714
198. Wolters A., Classen J., Kunesch E., et al. Measurements of transcallosally mediated cortical inhibition for differentiating parkinsonian syndromes. Mov Disord 19 (2004) 518-528
199. Zemaitaitis M.O., Kim S.Y., Halverson R.A., et al. Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy. J Neuropathol Exp Neurol 62 (2003) 173-184